Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:01 pm
| PEG Ratio | -30.09 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bayer CropScience Ltd operates in the agrochemicals and pesticides sector, a critical area given the increasing focus on sustainable agriculture. The company reported a revenue of ₹5,140 Cr for the fiscal year ending March 2023, marking a significant increase from ₹4,734 Cr in the previous year. However, in FY 2024, the revenue slightly declined to ₹5,106 Cr, before rising to ₹5,473 Cr in FY 2025. This trend demonstrates resilience in a sector often influenced by agricultural cycles and climatic conditions. Quarterly sales figures also reflect this variability, with the highest sales recorded in Jun 2023 at ₹1,740 Cr, which fell to ₹955 Cr by Dec 2023. The company has a comprehensive product portfolio, enabling it to cater to diverse agricultural needs, which is essential in maintaining its revenue streams amidst fluctuating market conditions.
Profitability and Efficiency Metrics
Bayer CropScience’s profitability metrics indicate a robust operational performance, with a reported net profit of ₹609 Cr for FY 2025. The operating profit margin (OPM) stood at 13%, reflecting a dip from the previous year’s 17%. Notably, the company maintained a return on equity (ROE) of 20.0% and a return on capital employed (ROCE) of 24.8%, both of which are commendable compared to industry averages. The interest coverage ratio (ICR) reported at 47.61x signifies excellent debt management, allowing the company to cover its interest obligations comfortably. However, the cash conversion cycle (CCC) stretched to 234 days, indicating potential inefficiencies in inventory and receivables management. The efficiency ratios suggest that while Bayer CropScience is profitable, it may need to optimize its operational processes to enhance cash flow and profitability further.
Balance Sheet Strength and Financial Ratios
The balance sheet of Bayer CropScience reflects a solid financial foundation, with total assets amounting to ₹5,246 Cr as of FY 2025. The company reported reserves of ₹3,079 Cr, which indicates a strong retained earnings position. Borrowings stood at a low ₹102 Cr, underscoring a conservative approach to leveraging and a healthy financial structure. The price-to-book value ratio (P/BV) was recorded at 7.76x, which is relatively high, suggesting that the market may be pricing in strong future growth potential. Additionally, the current ratio stood at 2.01, indicating sufficient liquidity to meet short-term obligations. However, the quick ratio of 0.94 raises concerns about the immediate liquidity position, especially in the face of potential downturns in sales. Overall, Bayer CropScience’s financial ratios exhibit a strong balance sheet, although the quick ratio suggests a need for cautious liquidity management.
Shareholding Pattern and Investor Confidence
Bayer CropScience’s shareholding structure reflects a stable and confident investor base, with promoters holding 71.44% of the company as of September 2025. This high level of promoter ownership typically instills confidence in other investors regarding the company’s long-term strategy and governance. Foreign institutional investors (FIIs) have increased their stake to 3.80%, while domestic institutional investors (DIIs) hold 11.22%. The public shareholding stands at 13.56%, indicating a balanced distribution of ownership. The number of shareholders has also grown to 58,109, demonstrating increasing retail interest. However, the declining trend in DIIs from 12.78% in December 2022 to 11.22% in September 2025 may raise questions about institutional confidence in the stock. While the strong promoter holding supports stability, the shifting dynamics among institutional investors warrant monitoring.
Outlook, Risks, and Final Insight
The outlook for Bayer CropScience appears cautiously optimistic, driven by its strong product portfolio and solid balance sheet. However, the company faces several risks, including fluctuations in raw material prices and regulatory challenges in the agrochemical sector. Additionally, the high cash conversion cycle suggests potential operational inefficiencies that could impact liquidity. On the positive side, the company’s strong ROE and ROCE ratios indicate efficient use of equity and capital, positioning it well for future growth. If Bayer CropScience can streamline its operations and improve its cash flow management, it stands to enhance its profitability further. Conversely, any adverse changes in agricultural policies or market demand could pose challenges. Overall, Bayer CropScience maintains a solid foundation but must navigate these risks to sustain its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,484 Cr. | 1,040 | 2,114/903 | 13.3 | 487 | 0.58 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 853 Cr. | 252 | 391/165 | 17.7 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 73.2 Cr. | 140 | 149/56.6 | 13.1 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,898 Cr. | 223 | 331/198 | 120 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 668 Cr. | 18.9 | 35.8/16.3 | 27.6 | 22.8 | 1.06 % | 12.9 % | 9.95 % | 1.00 |
| Industry Average | 10,921.05 Cr | 1,135.63 | 29.69 | 369.04 | 0.43% | 15.21% | 19.87% | 6.67 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,452 | 1,038 | 982 | 1,740 | 1,617 | 955 | 792 | 1,631 | 1,738 | 1,057 | 1,046 | 1,915 | 1,553 |
| Expenses | 1,214 | 952 | 777 | 1,315 | 1,312 | 827 | 695 | 1,317 | 1,554 | 1,037 | 876 | 1,566 | 1,348 |
| Operating Profit | 238 | 85 | 206 | 425 | 305 | 128 | 97 | 314 | 184 | 20 | 171 | 348 | 205 |
| OPM % | 16% | 8% | 21% | 24% | 19% | 13% | 12% | 19% | 11% | 2% | 16% | 18% | 13% |
| Other Income | 14 | 116 | 24 | 21 | 16 | 15 | 29 | 27 | 24 | 32 | 37 | 19 | 14 |
| Interest | 8 | 3 | 7 | 8 | 4 | 3 | 5 | 4 | 3 | 4 | 6 | 5 | 4 |
| Depreciation | 15 | 14 | 27 | 31 | 12 | 15 | 16 | 22 | 14 | 15 | 34 | 27 | 14 |
| Profit before tax | 229 | 184 | 195 | 406 | 306 | 124 | 105 | 316 | 190 | 34 | 168 | 335 | 200 |
| Tax % | 29% | 27% | 19% | 19% | 27% | 25% | 9% | 20% | 28% | -2% | 15% | 17% | 24% |
| Net Profit | 163 | 134 | 158 | 328 | 223 | 93 | 96 | 254 | 136 | 34 | 143 | 279 | 153 |
| EPS in Rs | 36.18 | 29.93 | 35.27 | 73.09 | 49.60 | 20.72 | 21.36 | 56.56 | 30.33 | 7.61 | 31.89 | 62.01 | 33.98 |
Last Updated: December 27, 2025, 9:38 pm
Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,553.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,915.00 Cr. (Jun 2025) to 1,553.00 Cr., marking a decrease of 362.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,348.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,566.00 Cr. (Jun 2025) to 1,348.00 Cr., marking a decrease of 218.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 205.00 Cr.. The value appears to be declining and may need further review. It has decreased from 348.00 Cr. (Jun 2025) to 205.00 Cr., marking a decrease of 143.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Jun 2025) to 13.00%, marking a decrease of 5.00%.
- For Other Income, as of Sep 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Jun 2025) to 14.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Jun 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 27.00 Cr. (Jun 2025) to 14.00 Cr., marking a decrease of 13.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 200.00 Cr.. The value appears to be declining and may need further review. It has decreased from 335.00 Cr. (Jun 2025) to 200.00 Cr., marking a decrease of 135.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Jun 2025) to 24.00%, marking an increase of 7.00%.
- For Net Profit, as of Sep 2025, the value is 153.00 Cr.. The value appears to be declining and may need further review. It has decreased from 279.00 Cr. (Jun 2025) to 153.00 Cr., marking a decrease of 126.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 33.98. The value appears to be declining and may need further review. It has decreased from 62.01 (Jun 2025) to 33.98, marking a decrease of 28.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:06 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,188 | 3,660 | 2,769 | 2,803 | 2,710 | 3,167 | 3,609 | 4,261 | 4,734 | 5,140 | 5,106 | 5,473 | 5,572 |
| Expenses | 2,768 | 3,144 | 2,334 | 2,389 | 2,300 | 2,684 | 2,883 | 3,450 | 3,923 | 4,216 | 4,147 | 4,783 | 4,827 |
| Operating Profit | 419 | 516 | 435 | 414 | 410 | 483 | 726 | 812 | 812 | 924 | 959 | 691 | 745 |
| OPM % | 13% | 14% | 16% | 15% | 15% | 15% | 20% | 19% | 17% | 18% | 19% | 13% | 13% |
| Other Income | 91 | 88 | 82 | 70 | 39 | 51 | -64 | 69 | 112 | 168 | 76 | 118 | 102 |
| Interest | 5 | 5 | 10 | 7 | 11 | 10 | 14 | 13 | 13 | 22 | 20 | 17 | 18 |
| Depreciation | 65 | 25 | 25 | 29 | 33 | 44 | 65 | 74 | 64 | 80 | 74 | 85 | 91 |
| Profit before tax | 441 | 574 | 482 | 448 | 404 | 480 | 583 | 794 | 847 | 990 | 941 | 707 | 737 |
| Tax % | 34% | 33% | 35% | 35% | 26% | 30% | 19% | 38% | 24% | 23% | 21% | 20% | |
| Net Profit | 290 | 383 | 315 | 291 | 300 | 337 | 474 | 493 | 645 | 758 | 740 | 568 | 609 |
| EPS in Rs | 79.06 | 104.59 | 89.13 | 82.31 | 87.41 | 98.18 | 105.58 | 109.72 | 143.58 | 168.71 | 164.77 | 126.38 | 135.49 |
| Dividend Payout % | 7% | 20% | 19% | 21% | 21% | 18% | 24% | 105% | 104% | 77% | 85% | 99% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.07% | -17.75% | -7.62% | 3.09% | 12.33% | 40.65% | 4.01% | 30.83% | 17.52% | -2.37% | -23.24% |
| Change in YoY Net Profit Growth (%) | 0.00% | -49.82% | 10.14% | 10.71% | 9.24% | 28.32% | -36.64% | 26.82% | -13.31% | -19.89% | -20.87% |
Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 0% |
| 3 Years: | -2% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -3% |
| 3 Years: | -1% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 20% |
Last Updated: September 5, 2025, 2:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 37 | 37 | 35 | 35 | 34 | 34 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 1,706 | 1,996 | 1,804 | 2,021 | 1,744 | 2,205 | 2,528 | 2,505 | 2,479 | 2,667 | 2,804 | 2,806 | 3,079 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 26 | 86 | 74 | 47 | 105 | 102 |
| Other Liabilities | 645 | 740 | 597 | 769 | 756 | 1,310 | 1,262 | 1,663 | 1,742 | 1,893 | 1,701 | 2,290 | 1,966 |
| Total Liabilities | 2,387 | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 | 5,191 |
| Fixed Assets | 228 | 322 | 290 | 342 | 334 | 440 | 468 | 425 | 468 | 462 | 414 | 470 | 585 |
| CWIP | 217 | 1 | 17 | 24 | 36 | 47 | 56 | 76 | 98 | 109 | 119 | 119 | 9 |
| Investments | 4 | 29 | 68 | 50 | 0 | 0 | 41 | 52 | 38 | 41 | 54 | 35 | 41 |
| Other Assets | 1,939 | 2,422 | 2,062 | 2,410 | 2,164 | 3,062 | 3,270 | 3,686 | 3,749 | 4,066 | 4,010 | 4,622 | 4,557 |
| Total Assets | 2,387 | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 | 5,191 |
Below is a detailed analysis of the balance sheet data for Bayer CropScience Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,079.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,806.00 Cr. (Mar 2025) to 3,079.00 Cr., marking an increase of 273.00 Cr..
- For Borrowings, as of Sep 2025, the value is 102.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 105.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,966.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,290.00 Cr. (Mar 2025) to 1,966.00 Cr., marking a decrease of 324.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,191.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,246.00 Cr. (Mar 2025) to 5,191.00 Cr., marking a decrease of 55.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 585.00 Cr.. The value appears strong and on an upward trend. It has increased from 470.00 Cr. (Mar 2025) to 585.00 Cr., marking an increase of 115.00 Cr..
- For CWIP, as of Sep 2025, the value is 9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 110.00 Cr..
- For Investments, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 4,557.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,622.00 Cr. (Mar 2025) to 4,557.00 Cr., marking a decrease of 65.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,191.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,246.00 Cr. (Mar 2025) to 5,191.00 Cr., marking a decrease of 55.00 Cr..
Notably, the Reserves (3,079.00 Cr.) exceed the Borrowings (102.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 419.00 | 516.00 | 435.00 | 414.00 | 410.00 | 483.00 | 724.00 | 786.00 | 726.00 | 850.00 | 912.00 | 586.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 57 | 53 | 72 | 89 | 81 | 73 | 65 | 77 | 69 | 69 | 63 |
| Inventory Days | 98 | 85 | 169 | 178 | 175 | 294 | 206 | 226 | 235 | 268 | 222 | 319 |
| Days Payable | 51 | 40 | 52 | 67 | 67 | 164 | 101 | 142 | 127 | 129 | 87 | 148 |
| Cash Conversion Cycle | 94 | 102 | 171 | 184 | 197 | 211 | 177 | 149 | 185 | 208 | 204 | 234 |
| Working Capital Days | 88 | 53 | 92 | 104 | 134 | 116 | 77 | 61 | 84 | 86 | 78 | 88 |
| ROCE % | 24% | 31% | 25% | 23% | 22% | 25% | 30% | 31% | 31% | 34% | 34% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 1,037,211 | 1.59 | 472.76 | 986,394 | 2025-12-15 03:03:08 | 5.15% |
| Nippon India Small Cap Fund | 559,898 | 0.37 | 255.2 | 531,460 | 2025-11-02 18:14:38 | 5.35% |
| Aditya Birla Sun Life Large Cap Fund | 349,249 | 0.51 | 159.19 | 336,808 | 2026-01-26 05:24:40 | 3.69% |
| Nippon India Growth Mid Cap Fund | 303,512 | 0.33 | 138.34 | N/A | N/A | N/A |
| Aditya Birla Sun Life MNC Fund | 230,758 | 2.94 | 105.18 | N/A | N/A | N/A |
| DSP Small Cap Fund | 180,663 | 0.49 | 82.35 | N/A | N/A | N/A |
| Bandhan ELSS Tax Saver Fund | 175,000 | 1.09 | 79.77 | 170,000 | 2025-12-15 03:03:08 | 2.94% |
| Bandhan Value Fund | 155,000 | 0.68 | 70.65 | 150,000 | 2026-01-26 07:39:08 | 3.33% |
| Tata India Pharma & HealthCare Fund | 92,824 | 3.23 | 42.31 | N/A | N/A | N/A |
| DSP Multicap Fund | 88,177 | 1.5 | 40.19 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.38 | 164.77 | 168.71 | 143.58 | 109.72 |
| Diluted EPS (Rs.) | 126.38 | 164.77 | 168.71 | 143.58 | 109.72 |
| Cash EPS (Rs.) | 145.41 | 181.40 | 186.57 | 158.08 | 126.19 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 634.83 | 634.61 | 604.03 | 562.20 | 568.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 634.83 | 634.61 | 604.03 | 562.20 | 568.00 |
| Dividend / Share (Rs.) | 125.00 | 140.00 | 130.00 | 150.00 | 115.00 |
| Revenue From Operations / Share (Rs.) | 1219.02 | 1136.57 | 1144.70 | 1054.43 | 949.06 |
| PBDIT / Share (Rs.) | 180.24 | 230.51 | 220.07 | 192.81 | 194.99 |
| PBIT / Share (Rs.) | 161.34 | 214.03 | 202.36 | 178.44 | 178.62 |
| PBT / Share (Rs.) | 157.55 | 209.66 | 220.51 | 188.60 | 176.95 |
| Net Profit / Share (Rs.) | 126.50 | 164.92 | 168.86 | 143.72 | 109.82 |
| PBDIT Margin (%) | 14.78 | 20.28 | 19.22 | 18.28 | 20.54 |
| PBIT Margin (%) | 13.23 | 18.83 | 17.67 | 16.92 | 18.82 |
| PBT Margin (%) | 12.92 | 18.44 | 19.26 | 17.88 | 18.64 |
| Net Profit Margin (%) | 10.37 | 14.51 | 14.75 | 13.63 | 11.57 |
| Return on Networth / Equity (%) | 19.92 | 25.98 | 27.95 | 25.56 | 19.33 |
| Return on Capital Employeed (%) | 23.96 | 32.03 | 31.31 | 29.74 | 30.05 |
| Return On Assets (%) | 10.82 | 16.10 | 16.20 | 14.82 | 11.63 |
| Asset Turnover Ratio (%) | 1.11 | 1.10 | 1.14 | 1.10 | 1.06 |
| Current Ratio (X) | 2.01 | 2.44 | 2.19 | 2.15 | 2.26 |
| Quick Ratio (X) | 0.94 | 1.48 | 1.18 | 1.24 | 1.41 |
| Inventory Turnover Ratio (X) | 2.80 | 1.48 | 1.39 | 1.82 | 2.17 |
| Dividend Payout Ratio (NP) (%) | 98.90 | 81.93 | 74.09 | 104.47 | 104.82 |
| Dividend Payout Ratio (CP) (%) | 86.04 | 74.48 | 67.06 | 94.98 | 91.22 |
| Earning Retention Ratio (%) | 1.10 | 18.07 | 25.91 | -4.47 | -4.82 |
| Cash Earning Retention Ratio (%) | 13.96 | 25.52 | 32.94 | 5.02 | 8.78 |
| Interest Coverage Ratio (X) | 47.61 | 52.81 | 44.31 | 67.11 | 69.48 |
| Interest Coverage Ratio (Post Tax) (X) | 34.41 | 38.78 | 30.35 | 46.49 | 39.73 |
| Enterprise Value (Cr.) | 21230.10 | 22377.29 | 17307.30 | 21584.03 | 22612.20 |
| EV / Net Operating Revenue (X) | 3.88 | 4.38 | 3.37 | 4.56 | 5.31 |
| EV / EBITDA (X) | 26.23 | 21.62 | 17.52 | 24.93 | 25.83 |
| MarketCap / Net Operating Revenue (X) | 4.04 | 4.61 | 3.54 | 4.73 | 5.59 |
| Retention Ratios (%) | 1.09 | 18.06 | 25.90 | -4.47 | -4.82 |
| Price / BV (X) | 7.76 | 8.26 | 6.70 | 8.86 | 9.34 |
| Price / Net Operating Revenue (X) | 4.04 | 4.61 | 3.54 | 4.73 | 5.59 |
| EarningsYield | 0.02 | 0.03 | 0.04 | 0.02 | 0.02 |
After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
- For Cash EPS (Rs.), as of Mar 25, the value is 145.41. This value is within the healthy range. It has decreased from 181.40 (Mar 24) to 145.41, marking a decrease of 35.99.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
- For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 140.00 (Mar 24) to 125.00, marking a decrease of 15.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,219.02. It has increased from 1,136.57 (Mar 24) to 1,219.02, marking an increase of 82.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 180.24. This value is within the healthy range. It has decreased from 230.51 (Mar 24) to 180.24, marking a decrease of 50.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 161.34. This value is within the healthy range. It has decreased from 214.03 (Mar 24) to 161.34, marking a decrease of 52.69.
- For PBT / Share (Rs.), as of Mar 25, the value is 157.55. This value is within the healthy range. It has decreased from 209.66 (Mar 24) to 157.55, marking a decrease of 52.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.50. This value is within the healthy range. It has decreased from 164.92 (Mar 24) to 126.50, marking a decrease of 38.42.
- For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has decreased from 20.28 (Mar 24) to 14.78, marking a decrease of 5.50.
- For PBIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 18.83 (Mar 24) to 13.23, marking a decrease of 5.60.
- For PBT Margin (%), as of Mar 25, the value is 12.92. This value is within the healthy range. It has decreased from 18.44 (Mar 24) to 12.92, marking a decrease of 5.52.
- For Net Profit Margin (%), as of Mar 25, the value is 10.37. This value exceeds the healthy maximum of 10. It has decreased from 14.51 (Mar 24) to 10.37, marking a decrease of 4.14.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has decreased from 25.98 (Mar 24) to 19.92, marking a decrease of 6.06.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.96. This value is within the healthy range. It has decreased from 32.03 (Mar 24) to 23.96, marking a decrease of 8.07.
- For Return On Assets (%), as of Mar 25, the value is 10.82. This value is within the healthy range. It has decreased from 16.10 (Mar 24) to 10.82, marking a decrease of 5.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 1.10 (Mar 24) to 1.11, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.44 (Mar 24) to 2.01, marking a decrease of 0.43.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.94, marking a decrease of 0.54.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.80. This value is below the healthy minimum of 4. It has increased from 1.48 (Mar 24) to 2.80, marking an increase of 1.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 98.90. This value exceeds the healthy maximum of 50. It has increased from 81.93 (Mar 24) to 98.90, marking an increase of 16.97.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 86.04. This value exceeds the healthy maximum of 50. It has increased from 74.48 (Mar 24) to 86.04, marking an increase of 11.56.
- For Earning Retention Ratio (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 40. It has decreased from 18.07 (Mar 24) to 1.10, marking a decrease of 16.97.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 13.96. This value is below the healthy minimum of 40. It has decreased from 25.52 (Mar 24) to 13.96, marking a decrease of 11.56.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 47.61. This value is within the healthy range. It has decreased from 52.81 (Mar 24) to 47.61, marking a decrease of 5.20.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 34.41. This value is within the healthy range. It has decreased from 38.78 (Mar 24) to 34.41, marking a decrease of 4.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 21,230.10. It has decreased from 22,377.29 (Mar 24) to 21,230.10, marking a decrease of 1,147.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.38 (Mar 24) to 3.88, marking a decrease of 0.50.
- For EV / EBITDA (X), as of Mar 25, the value is 26.23. This value exceeds the healthy maximum of 15. It has increased from 21.62 (Mar 24) to 26.23, marking an increase of 4.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
- For Retention Ratios (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 30. It has decreased from 18.06 (Mar 24) to 1.09, marking a decrease of 16.97.
- For Price / BV (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has decreased from 8.26 (Mar 24) to 7.76, marking a decrease of 0.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
- Net Profit Margin: 10.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.96% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.92% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 34.41
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.7 (Industry average Stock P/E: 29.69)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.37%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Bayer House, Central Avenue, Mumbai Maharashtra 400607 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pankaj Ramanbhai Patel | Chairman & Ind.Dire (Non-Exe) |
| Mr. Simon Thorsten Wiebusch | Vice Chairman & Mng.Director |
| Mr. Vinit Rajesh Jindal | Executive Director & CFO |
| Dr. Thomas Hoffmann | Non Exe.Non Ind.Director |
| Ms. Jana Marlen Ackermann | Non Exe.Non Ind.Director |
| Ms. Radhika Rajan | Ind. Non-Executive Director |
| Mr. Sekhar Natarajan | Ind. Non-Executive Director |
| Mr. Sanjiv Rangrass | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Bayer CropScience Ltd?
Bayer CropScience Ltd's intrinsic value (as of 11 February 2026) is ₹3915.60 which is 16.62% lower the current market price of ₹4,696.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹21,122 Cr. market cap, FY2025-2026 high/low of ₹6,540/4,217, reserves of ₹3,079 Cr, and liabilities of ₹5,191 Cr.
What is the Market Cap of Bayer CropScience Ltd?
The Market Cap of Bayer CropScience Ltd is 21,122 Cr..
What is the current Stock Price of Bayer CropScience Ltd as on 11 February 2026?
The current stock price of Bayer CropScience Ltd as on 11 February 2026 is ₹4,696.
What is the High / Low of Bayer CropScience Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bayer CropScience Ltd stocks is ₹6,540/4,217.
What is the Stock P/E of Bayer CropScience Ltd?
The Stock P/E of Bayer CropScience Ltd is 34.7.
What is the Book Value of Bayer CropScience Ltd?
The Book Value of Bayer CropScience Ltd is 695.
What is the Dividend Yield of Bayer CropScience Ltd?
The Dividend Yield of Bayer CropScience Ltd is 2.66 %.
What is the ROCE of Bayer CropScience Ltd?
The ROCE of Bayer CropScience Ltd is 24.8 %.
What is the ROE of Bayer CropScience Ltd?
The ROE of Bayer CropScience Ltd is 20.0 %.
What is the Face Value of Bayer CropScience Ltd?
The Face Value of Bayer CropScience Ltd is 10.0.